Aim: To investigate the predictive value of and mutation status in colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Methods: In this study, a total of 315 patients with histologically proven CRC were enrolled from Yangpu Hospital affiliated to Shanghai Tongji University between 2007 and 2011. Of these patients, 241 with stage II/III CRC received 5-fluorouracil-based adjuvant chemotherapy. Formalin-fixed paraffin-embedded lesion samples of the patients with curatively resected CRC were collected. Next-generation sequencing was performed to identify somatic gene mutations. The correlation of and mutation status with overall survival (OS) was analyzed using a Cox proportional hazard model and the Kaplan-Meier method.
Results: Among the 241 patients with stage II/III in this cohort, the and/or mutation was detected in 177 patients, among which 54 patients had and double mutations. The or mutation was not significantly correlated with OS in univariate and multivariate analyses. Compared with patients without and mutations, those with double mutations showed a significantly worse survival (univariate HR = 2.21; 95%CI: 1.15-4.24; multivariate HR = 2.02; 95%CI: 1.04-3.91). The mutation located in the kinase domain showed a trend toward a shorter OS compared with wild-type tumors (multivariate HR = 1.56; 95%CI: 1.00-2.44; = 0.052). The Kaplan-Meier curve showed that patients harboring the mutation located in the kinase domain had a worse clinical outcome than those with wild-type status (Log-rank = 0.041).
Conclusion: Double mutation of and is correlated with a shorter OS in stage II/III CRC patients treated with 5-fluorouracil-based therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799864 | PMC |
| http://dx.doi.org/10.3748/wjg.v24.i5.631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soluble Herpes Virus Entry Mediator and Type II/III Interferons Are Upregulated in Primary Biliary Cholangitis.
Int J Mol Sci
January 2025
The Roger Williams Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London & Foundation for Liver Research, London SE5 9NT, UK.
Bacterial translocation-induced inflammation and immune dysfunction are recognised factors contributing to the pathogenesis of primary biliary cholangitis (PBC). However, the specific involvement of interferons (IFNs) and soluble checkpoints (sol-CRs) in shaping the immune landscape in PBC patients remains unexplored. Furthermore, the influence of ursodeoxycholic acid (UDC) on these immune mediators is unknown.
View Article and Find Full Text PDFA Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients.
Cancers (Basel)
January 2025
Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
Background: Neoadjuvant systemic therapy is the preferred treatment approach for stage II-III HER2-positive breast cancer (BC). Real-life data comparing regimens with or without anthracyclines combined with two HER2 drugs is lacking. We compared the efficacy and toxicity of two commonly used regimens.
View Article and Find Full Text PDFFemale Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cancers (Basel)
January 2025
Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON M5G 1Z5, Canada.
The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving relapse-free survival rates in high-risk stage II-III disease. With the increasing use of ICI, secondary concerns have emerged regarding the impact of cancer drugs on fertility and reproductive health among women of childbearing potential, especially in early-stage cancer settings.
View Article and Find Full Text PDFAssociation of Increased CT-Attenuation of Visceral Adipose Tissue After Surgery with Poor Survival Outcomes in Patients with Stage II-III Gastric Cancer: A Retrospective Cohort Study.
Cancers (Basel)
January 2025
Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 31151, Republic of Korea.
Background/objectives: This study aimed to investigate whether post-operative changes in the computed tomography (CT)-attenuation of subcutaneous (SAT) and visceral (VAT) adipose tissues were significantly associated with recurrence-free survival (RFS), peritoneal RFS, and overall survival (OS) in patients with stage II-III gastric cancer.
Methods: This retrospective study analyzed 243 patients with stage II-III gastric cancer who underwent curative surgery. CT-attenuation values of SAT (SAT HU) and VAT (VAT HU) were measured from non-contrast-enhanced abdominopelvic CT images taken pre-operatively and 6 months post-operatively.
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Breast Cancer Res
January 2025
Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Background: The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease.
Methods: PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!